Publication Venue For
HIV stigma and viral load among African-American women receiving treatment for HIV.
HIV stigma and viral load among African-American women receiving treatment for HIV..
Poverty stigma is associated with suboptimal HIV care and treatment outcomes among women living with HIV in the United States.
Kidney disease in Africans with HIV and tuberculosis.
Longitudinal association between internalized HIV stigma and antiretroviral therapy adherence for women living with HIV: The mediating role of depression.
Increased influenza-specific antibody avidity in HIV-infected women compared with HIV-infected men on antiretroviral therapy.
Female genital tract shedding of HIV-1 is rare in women with suppressed HIV-1 in plasma
Social Harms in Female-INITIATED hiv prevention method RESEARCH: State of the evidence
Racial differences in human papilloma virus types amongst United States women with HIV and cervical precancer.
Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.
Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individuals: how much viral load history is enough?.
Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy.
Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status.
Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status..
Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ : CD8+ ratio..
Long-term trends in CD4 cell counts, CD8 cell counts, and the CD4: CD8 ratio: ART Cohort Collaboration (ART-CC) Study.
Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation..
Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
Trends in antiretroviral therapy prescription, durability and modification: New drugs, more changes, but less failure.
Virologic suppression and CD4 + cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens.
Beyond binary retention in HIV care: Predictors of the dynamic processes of patient engagement, disengagement, and re-entry into care in a US clinical cohort.
HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy.
Progressive lentivirus infection induces natural killer cell receptor-expressing B cells in the gastrointestinal tract.
Racial differences in calculated bioavailable Vitamin D with Vitamin D/calcium supplementation.
Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries.
CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.
Cervical cancer screening intervals and management for women living with HIV: A risk benchmarking approach.
Relationship between ever reporting depressive symptoms and all-cause mortality in a cohort of HIV-infected adults in routine care.
Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy.
Smoking, HIV, and risk of pregnancy loss.
Interpreting the influence of race and cognitive activity on neurocognition in adults aging with HIV.
Increased glucose transporter-1 expression on intermediate monocytes from HIV-infected women with subclinical cardiovascular disease.
Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.
Assessing efficacy of a retention-in-care intervention among HIV patients with depression, anxiety, heavy alcohol consumption and illicit drug use.
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.
High rate of lymphoma among a UK cohort of adolescents with vertically acquired HIV-1 infection transitioning to adult care in the era of antiretroviral therapy.
A prospective study of anal cancer screening in HIV-positive and negative MSM.
Cost considerations in the current antiretroviral era.
Normal T-cell activation in elite controllers with preserved CD4 + T-cell counts.
Disclosure of pharmacokinetic drug results to understand nonadherence.
Intimate partner violence and engagement in HIV care and treatment among women: A systematic review and meta-analysis.
The effect of antidepressant treatment on HIV and depression outcomes: Results from a randomized trial.
Examining the association between male circumcision and sexual function: Evidence from a British probability survey.
Time above 1500 copies: a viral load measure for assessing transmission risk of HIV-positive patients in care.
Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients..
A better screening tool for HIV-associated neurocognitive disorders: Is it what clinicians need?.
Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.
Testosterone replacement therapy among HIV-infected men in the CFAR network of integrated clinical systems.
Mitochondrial DNA variation and virologic and immunological HIV outcomes in African Americans.
Decline in locomotor functions over time in HIV-infected patients.
Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.
Efficacy and safety of Maraviroc vs. Efavirenz in treatment-naive patients with HIV-1: 5-year findings.
Deficient synthesis of class-switched, HIVneutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.
Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.
HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periods.
Association of early HIV viremia with mortality after HIV-associated lymphoma.
Clinical, radiological and laboratory features of human metapneumovirus lower respiratory tract infection in HIV-positive patients: A case series.
Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy.
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009..
Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection.
Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in utero.
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.
Replication of RYR3 gene polymorphism association with cIMT among HIV-infected whites.
Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era.
The association between Mycoplasma genitalium and HIV-1 acquisition in African women..
Reply to 'pharmacokinetic concerns related to darunavir/ritonavir plus raltegravir combination therapy trial'.
Mental health disorders and the risk of AIDS-defining illness and death in HIV-infected veterans.
The association between Mycoplasma genitalium and HIV-1 acquisition in African women.
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).
IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation.
Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy.
Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.
Virologic and immunologic response to HAART, by age and regimen class.
Periconception pre-exposure prophylaxis to prevent HIV transmission: Benefits, risks, and challenges to implementation.
Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy.
Outcomes after virologic failure of first-line ART in South Africa.
A genome-wide association study of carotid atherosclerosis in HIV-infected men.
Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection.
A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.
HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation.
Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements..
Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study.
HIV viremia and changes in kidney function.
Host genetics and HIV-1 viral load set-point in African-Americans.
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.
Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes..
Does short-term virologic failure translate to clinical events in antiretroviral- naive patients initiating antiretroviral therapy in clinical practice
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.
Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia.
Treatment response in acute/early infection versus advanced AIDS: Equivalent first and second phases of HIV RNA decline.
Association of antiretroviral therapy with fibrinogen levels in HIV-infection.
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? The Antiretroviral Therapy Cohort Collaboration (ART-CC).
Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents.
Prevalence and factors associated with dry skin in HIV infection: The FRAM study.
Efficacy of boosted protease inhibitor monotherapy in patients with complex medical problems.
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.
Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe.
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.
Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic.
Cohort- and time-specific associations of CTLA4 genotypes with HIV-1 disease progression.
Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity.
Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.
Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients.
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.
Monocyte derived dendritic cells from HIV-1 infected individuals partially reconstitute CD4 T-cell responses.
Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy.
A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers.
Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia.
Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy.
Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals.
CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides.
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
Determinants of HIV drug resistance mutations in plasma virus after treatment interruption.
Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count.
Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study.
Factors associated with chronic renal failure in HIV-infected ambulatory patients..
Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings.
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine.
Human papillomavirus infection and abnormal cytology of the anus in HIV-infected and uninfected adolescents.
The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy..
17 Suppl 4.
Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents.
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.
Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).
Pneumocystis carinii pneumonia and cytomegalovirus infection in children with vertically acquired HIV infection.
Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients.
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884.
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: Results of adult AIDS clinical trials group protocol 370.
Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine.
Short tandem repeat methodology for genotypic identification of single-person versus multi-person use of syringes.
Partner type and condom use.
Neurological outcomes in late HIV infection: Adverse impact of neurological impairment on survival and protective effect of antiviral therapy.
Predictors of optimal virological response to potent antiretroviral therapy.
Cerebrospinal fluid S-100b concentrations in patients with HIV infection .
HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women .
Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents.
Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults.
Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team..
The new HIV therapies: Implications for HIV prevention .
Cerebral proton magnetic resonance spectroscopy in asymptomatic HIV infection.
Atovaquone is effective treatment for the symptoms of gastrointestinal microsporidiosis in HIV-1-infected patients.
Cerebral proton magnetic resonance spectroscopy in cytomegalovirus encephalitis and HIV leucoencephalopathy/encephalitis .
Vitamin A depletion in HIV infection and AIDS .
Seroconversion in patients attending sexually transmitted disease clinics.
Persistent anaemia in HIV-infected individuals due to parvovirus B19 infection .
Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction.
Expression of HIV-1 in the cerebrospinal fluid detected by the polymerase chain reaction and its correlation with central nervous system disease.
HTLV-I and HIV-1-associated neurologic abnormalities; syphilis as a confounding factor.
Reversible zidovudine-induced pure red-cell aplasia.